Compare Crispr Therapeutics AG (CRSP) vs Matson Inc (MATX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Matson Inc — how do they compare? Crispr Therapeutics AG trades at $50.54 (market cap $4.97B), while Matson Inc trades at $210.44 (market cap $6.38B). The key difference: Matson Inc is the larger of the two by market cap, and Matson Inc pays a 0.72% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | MATX | |
|---|---|---|
Market Cap | $4.97B | $6.38B |
Sector | Health | Technology |
52-Week High | $76.78 | $210.95 |
52-Week Low | $44.34 | $88.05 |
Enterprise Value | $3.32B | $6.98B |
Dividend Yield | — | 0.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Matson (MATX) trades at $205.15, up 0.19% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a 12.92% net income margin and consistent earnings beats in recent quarters. Recent developments include a dividend increase to $0.38 per share and progress on its LNG-powered vessel construction program, highlighting operational strength and shareholder returns.
The outlook for MATX is positive, supported by niche Pacific shipping routes and resilient earnings. Key opportunities include growth in expedited China service and share repurchases. Risks involve exposure to trade volatility and potential margin pressure from higher costs. Analyst consensus is bullish with 64% buy ratings, but investors should monitor global trade flows and competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →
